Sumitomo Dainippon Operating Profit Plummets 50% on Drug Price Cut, Generic Erosions

Sumitomo Dainippon Pharma President Hiroshi Nomura Sumitomo Dainippon Pharma suffered a plunge of over 50% in the first half of FY2018 as its Japan revenue was battered by the April 2018 drug price revision and relentless generic inroads, the company...read more